Middle East observational study in metastatic soft tissue sarcoma: an epidemiological study on the treatment patterns (MOON)

被引：0
|
作者：
Muhammad A. Memon
Burcak Karaca
Rasha Aboelhassan
Mohsen Barsoum
Mustafa Erman
Mert Basaran
Alper Sevinc
Djedi Hanene
Cassandra Slader
Virginia Pilipovic
Kerboua Esma
Bouzid Kamel
机构：
[1] King Faisal Specialist Hospital and Research Center,Medical Oncology
[2] Ege University,Department of Medical Oncology
[3] Nasser Institute for Research and Treatment,undefined
[4] National Cancer Institute Cairo University,undefined
[5] Hacettepe University,undefined
[6] Istanbul University,undefined
[7] Medical Park Gaziantep Hospital,undefined
[8] Anticancer Center,undefined
[9] Novartis Pharma AG,undefined
[10] Centre Pierre et Marie Curie,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2018年 / 144卷
关键词：
Soft tissue sarcomas; Real-world outcomes; Epidemiological study; Middle East; Pazopanib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2219 / 2229
页数：10
相关论文
共 50 条
  • [21] Characteristics and Treatment Patterns of Patients with Type 2 Diabetes Mellitus in the Middle East and Africa Cohort of the DISCOVER Study Program: a Prospective Study
    Khalid Al-Rubeaan
    Mohamed Alsayed
    Abdullah Ben-Nakhi
    Fahri Bayram
    Akram Echtay
    Ahmed Hadaoui
    Khadija Hafidh
    Kevin Kennedy
    Adri Kok
    Rachid Malek
    Viraj Rajadhyaksha
    Suzanne V. Arnold
    Diabetes Therapy, 2022, 13 : 1339 - 1352
  • [22] Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study
    Mustafa, Erman
    Bivas, Biswas
    Pongwut, Danchaivijitr
    Chen Lingwu
    Wong, Yoke Fui
    Hashem, Tarek
    Lim, Chun Sen
    Karabulut, Bulent
    Chung, Hsiao-Jen
    Chikatapu, Chandra
    Ingles, Sara
    Slimane, Khemaies
    Kanesvaran, Ravindran
    BMC CANCER, 2021, 21 (01)
  • [23] Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study
    Mustafa Erman
    Bivas Biswas
    Pongwut Danchaivijitr
    Lingwu Chen
    Yoke Fui Wong
    Tarek Hashem
    Chun Sen Lim
    Bulent Karabulut
    Hsiao-Jen Chung
    Chandrasekhar Chikatapu
    Sara Ingles
    Khemaies Slimane
    Ravindran Kanesvaran
    BMC Cancer, 21
  • [24] The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study
    Nakamura, Tomoki
    Tsukushi, Satoshi
    Asanuma, Kunihiro
    Katagiri, Hirohisa
    Ikuta, Kunihiro
    Nagano, Akihito
    Kozawa, Eiji
    Yamada, Satoshi
    Shido, Yoji
    Yamada, Kenji
    Kawanami, Katsuhisa
    Ishimura, Daisuke
    Sudo, Akihiro
    Nishida, Yoshihiro
    CLINICAL & EXPERIMENTAL METASTASIS, 2019, 36 (04) : 343 - 350
  • [25] Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma
    Ranieri, Girolamo
    Mammi, Maria
    Di Paola, Eugenio Donato
    Russo, Emilio
    Gallelli, Luca
    Citraro, Rita
    Gadaleta, Cosmo Damiano
    Marech, Ilaria
    Ammendola, Michele
    De Sarro, Giovambattista
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 89 (02) : 322 - 329
  • [26] A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)
    Veitch, Zachary
    Zer, Alona
    Loong, Herbert
    Salah, Samer
    Masood, Maryam
    Gupta, Abha
    Bradbury, Penelope A.
    Hogg, David
    Wong, Andrew
    Kandel, Rita
    Charames, George S.
    Razak, Albiruni R. Abdul
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [27] Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols
    Ferrari, Andrea
    Trama, Annalisa
    De Paoli, Angela
    Bergeron, Christophe
    Merks, Johannes H. M.
    Jenney, Meriel
    Orbach, Daniel
    Chisholm, Julia C.
    Gallego, Soledad
    Glosli, Heidi
    De Salvo, Gian Luca
    Botta, Laura
    Gatta, Gemma
    Bisogno, Gianni
    PEDIATRIC BLOOD & CANCER, 2017, 64 (06)
  • [28] High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group
    Nielsen, OS
    Dombernowsky, P
    Mouridsen, H
    Crowther, D
    Verweij, J
    Buesa, J
    Steward, W
    Daugaard, S
    van Glabbeke, M
    Kirkpatrick, A
    Tursz, T
    BRITISH JOURNAL OF CANCER, 1998, 78 (12) : 1634 - 1639
  • [29] The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study
    Nakamura, Tomoki
    Matsumine, Akihiko
    Kawai, Akira
    Araki, Nobuhito
    Goto, Takahiro
    Yonemoto, Tsukasa
    Sugiura, Hideshi
    Nishida, Yoshihiro
    Hiraga, Hiroaki
    Honoki, Kanya
    Yasuda, Taketoshi
    Boku, Shogen
    Sudo, Akihiro
    Ueda, Takafumi
    CANCER, 2016, 122 (09) : 1408 - 1416
  • [30] A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial
    Annika Karch
    Armin Koch
    Viktor Grünwald
    Trials, 17
12345